Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BioVascular Inc.

Latest From BioVascular Inc.

J.P. Morgan Notebook: Monday, January 13

Welcome to “The Pink Sheet” DAILY’s round-up of news and notes from the first full day of the 2014 J.P. Morgan health care conference, including chats with the CEOs of Elcelyx Therapeutics and Arecor, news from Juno Therapeutics and Galena Biopharma, and more.

BioPharmaceutical Business Strategies

BioVascular Inc.

BioVascular is a beneficiary of Merck KGAA's incubator program. launched to encourage start-up companies to develop Merck's shelved technologies. BioVascular gained rights to saratin, a protein originally isolated from leech saliva. Saratin's ability to reduce platelet adhesion and the complications that can arise from it give it a number of potential applications, but BioVascular's initial focus is on vascular surgery, specifically the prevention of intimal hyperplasia that leads to graft failure.
BioPharmaceutical Business Strategies

Cardiovascular Drug Start-Ups

The cardiovascular drug marketplace has the dubious distinction of being the largest therapeutic category in terms of revenue, unmet need and mortality, while at the same time being the only area experiencing decreasing growth. Revenues will start to plummet starting in 2012 when the world's two largest CV drugs--Lipitor and Plavix--go generic. To help pharmas replace these and other aging drugs in their pipelines, Windhover's Therapeutic Alliances conference presents the "top 10" unpartnered clinical-stage cardiovascular programs.
BioPharmaceutical Legal Issues
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • BioVascular Inc.
  • Senior Management
  • John Parrish, CEO
    Alison J Pilgrim, MD, PhD, CMO, VP, Clin. Dev.
    Eric Karpinski, VP, Bus. Dev.
  • Contact Info
  • BioVascular Inc.
    Phone: (858) 455-5000
    12230 El Camino Real
    Ste. 100
    San Diego, CA 92130